GLP-1 Agonist Anti-Fibrotic Repurposing
Idiopathic Pulmonary Fibrosis · GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
Mechanism
GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs
Development stage
Phase I/II (repurposing)
Evidence level
Level 2 (Repositioning)
Developer
Novo Nordisk / Eli Lilly
Overview
Liraglutide decreased collagen expression in experimental lung fibrosis, restored ACE2 levels, increased surfactant production. Semaglutide FDA-approved Jan 2025 for kidney fibrosis protection. Anti-inflammatory meta-analysis confirms CRP/IL-6 reduction. GLP-1 receptors present on alveolar epithelium. Fastest repurposing path — already FDA-approved, safety profile established.
Explore related
Medical disclaimer. This page summarizes research about GLP-1 Agonist Anti-Fibrotic Repurposing for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.